Kliniko-farmakologicheskoe obosnovanie primeneniya moksifloksatsina v terapii vospalitel'nykh zabolevaniy organov malogo taza
- Authors: Zharkova LP1
-
Affiliations:
- Issue: Vol 14, No 6 (2012)
- Pages: 8-13
- Section: Articles
- URL: https://gynecology.orscience.ru/2079-5831/article/view/33280
- ID: 33280
Cite item
Full Text
Abstract
References
- Рациональная фармакотерапия в акушерстве и гинекологии. Руководство для практических врачей. Под ред. В.И.Кулакова, В.Н.Серова. М.: Литтерра, 2005; с. 724-7.
- Справочник по акушерству, гинекологии и перинатологии. Под ред. Г.М.Савельевой. М.: МИА, 2006; с. 487-501.
- Banikarim C, Chacko MR. Pelvic inflammatory disease in adolescents. Semin Pediatr Infect Dis 2005; 16 (3): 175-80.
- Серов В.Н, Тихомиров А.Л. Современные принципы терапии воспалительных заболеваний женских половых органов. Методическое пособие. М., 2002.
- Beigi RH, Wiesenfeld HC. Pelvic inflammatory disease: new diagnostic criteria and treatment. Obstet Gynecol Clin North Am 2003; 30 (4): 777-93.
- Тихомиров А.Л., Сарсания С.И. Воспалительные заболевания женских половых органов. Брошюра практического гинеколога, 2007.
- Тихомиров А.Л. Значение адекватной антибактериальной терапии воспалительных заболеваний органов малого таза для сохранения репродуктивного женского здоровья. Трудный пациент. 2010; 8 (1-2): 9-12.
- Ершов Г.В., Бочкарев Д.Н., Смоленов И.В. Этиологическая структура и резистентность возбудителей воспалительных заболеваний органов малого таза у женщин. Клин. микробиология и антимикроб. химиотерапия. 2004; 6 (2): 193-200.
- Boeke AJ. The risk of pelvic inflammatory disease with urogenital infection with Chlamydia trachomatis. Ned Tijdschr Geneeskd 2005; 16 (149): 878-84.
- CDC. Sexually Transmitted Disease Treatment Guidelines. Pelvic Inflammatory Disease. MMWR 2010; 59: RR-12.
- Cohen CR, Manhart LE, Bukusi EA et al. Association between Mycoplasma genitalium and acute endometritis. Lancet 2002; 359: 765-6.
- RCOG Green Top Guidelines-Management of Pelvic Inflammatory Disease (2003, 2009). www.rcog.org.uk
- Clarke LM, Duerr А, Yeung КН. Recovery of cytomegalovirus and herpes simplex virus from upper and lower genital tract specimens obtained from women with pelvic inflammatory disease. J Infect Dis 1997; 1 (176): 286-8.
- Ross JD. Is Mycoplasma genitalium a cause of pelvic inflammatory disease? Infect Dis Clin North Am 2005; 19 (2): 407-13.
- Performance Standards for Antimicrobial Susceptibility Testing. National Committee for Clinical and Laboratory Standards (NCCLS) 2001; 21 (1): 123.
- Практическое руководство по антиинфекционной химиотерапии. Под ред. Л.С.Страчунского, Ю.Б.Белоусова, С.Н.Козлова. М., 2007; с. 294-5.
- Страчунский Л.С., Кречиков В.А. Моксифлоксацин - фторхинолон нового поколения с широким спектром активности. Клин. микробиология и антимикроб. химиотерапия. 2001; 3 (3): 243-59.
- Страчунский Л.С., Веселов А.В., Кречиков В.А. Моксифлоксацин: настоящее и будущее в ступенчатой терапии. Клин. микробиология и антимикроб. химиотерапия. 2003; 5 (1): 19-31.
- MacGowan A, Bowker K, Holt H, Wootton M et al. BAY 12-8039, a new 8-methoxy-quinolone: comparative in-vitro activity with nine other antimicrobials against anaerobic bacteria. J Antimicrob Chemother 1997; 40: 503-9.
- Wise R, Andrews J, Marshall G, Hartman G. Pharmacokinetics and inflammatory-fluid penetration of moxifloxacin following oral or intravenous administration. Antimicrob Agents Chemother 1999; 43: 1508-10.
- Lettieri J, Vargas R, Agarwal V, Liu P. Effect of food on the pharmacokinetics of a single oral dose of moxifloxacin 400 mg in healthy male volunteers. Clin Pharmacokinet 2001; 40 (Suppl. 1): 19-25.
- Ballow C, Lettieri J, Agarwal V, Liu P et al. Absolute bioavailability of moxifloxacin. Clin Ther 1999; 21: 513-22.
- Lubasch A, Keller I, Borner K, Koeppe P et al. Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin and moxifloxacin after single oral administration in healthy volunteers. Antimicrob Agents Chemother 2000; 44: 2600-3.
- Stass H, Kubitza D. Effects of dairy products on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in healthy volunteers. Clin Pharmacokinet 2001; 40 (Suppl. 1): 33-8.
- Sullivan J, Lettieri J, Liu P, Heller A. The influence of age and gender on the pharmacokinetics of moxifloxacin. Clin Pharmacokinet 2001; 40 (Suppl. 1): 11-8.
- Stass H, Halabi A, Delesen H. No dose adjustment needed for patients with renal impairment receiving oral BAY 12-8039 (M). Proceedings of the 38th ICAAC, 1998; San Diego, USA; p. 5.
- Stass H, Kubitza D. No dose adjustment is needed for moxifloxacin (MOX) in subjects suffering from hepatic impairment (HI). Clin Microb Infection 1999; 5 (Suppl. 3): 291.
- Zhanel G, Walters M, Karlowsky J, Laing N et al. Activity of free (unbound) fluoroquinolone serum concentrations versus multi-drug resistant Streptococcus pneumoniae using an in vitro pharmacodynamic model. Proceedings of the 40th ICAAC, 2000; Toronto, Canada; p. 7.
- Wright D, Brown G, Peterson M, Rotschafer J. Application of fluoroquinolones pharmacodynamics. J Antimicrob Chemother 2000; 46: 669-83.
- Boswell F, Andrews J, Wise R, Dalhoff A. Bactericidal properties of moxifloxacin and post-antibiotic effect. J Antimicrob Chemother 1999; 43 (Suppl. B): 43-9.
- Ricci V, Piddock L. Characterization of the QRDR of gyrA of Bacteroides fragilis and role in fluoroquinolone resistance. Proceedings of the 38th ICAAC, 1998; San Diego, USA; p. 121.
- Nord C, Edlund C. Susceptibility of anaerobic bacteria to BAY 12-8039, a new methoxyquinolone. Clin Microb Infection 1997; 3 (Suppl. 2): 285.
- Kubin R, Reiter C. Safety update of moxifloxacin: a current review of clinical trials and post-marketing observational studies. Proceedings of the 40th ICAAC, 2000; Toronto, Canada; p. 477.
- Kretchikov VA, Dekhnich AV, Startchounski LS. Comparative activity of old and new quinolones against nosocomial Staphylococcus aureus. Proceeding of 12th ECCMID, 2002; Milan, Italy. Abstract P1145.
- Bebear CM, Renaudin H, Boudjadja A, Bebear C. In vitro activity of BAY 12-8039, a new fluoroquinolone against mycoplasmas. Antimicrob Agents Chemother 1998; 42: 703-4.
- Takahata M, Shimakura M, Hori R et al. In vitro and in vivo efficacies of T-3811ME (BMS-284756) against Mycoplasma pneumoniae. Antimicrob Agents Chemother 2001; 45: 312-5.
- Ullmann U, Schubert S, Krausse R. Comparative in-vitro activity of levofloxacin, other fluoroquinolones, doxycycline and erythromycin against Ureaplasma urealyticum and Mycoplasma hominis. J Antimicrob Chemother 1999; 43 (Suppl. C): 33-6.
- Stass H, Kubitza D. Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man. J Antimicrob Chemother 1999; 43 (Suppl. B): 83-90.
- Kubin R, Reiter C. Safety update of moxifloxacin: a current review of clinical trials and post-marketing observational studies. Proceedings of the 40th ICAAC, 2000; Toronto, Canada; p. 477.
- Springsklee M, Reiter C, Meyer J. Safety and Tolerability Profile of Moxifloxacin (MXF). Clin Microb Infection 1999; 5 (Suppl. 3): 140.
- Fogarty C, Grossman C, Williams J, Haverstock D et al. Efficacy and safety of moxifloxacin vs clarithromycin for community-acquired pneumonia. Infect Med 1999; 16: 748-63.
- Hoffken G, Meyer H, Sprenger K, Verhoef L. Efficacy and safety of moxifloxacin (MXF) vs clarithromycin (Кларитро) for the treatment of community-acquired pneumonia (CAP). J Antimicrob Chemother 1999; 44 (Suppl. A): 127.
- Chodosh S, DeAvate C, Haverstock D, Aneiro L et al. Short-course moxifloxacin therapy for treatment of acute bacterial exacerbations of chronic bronchitis. Resp Med 2000; 94: 18-27.
- Wilson R, Kubin R, Ballin I et al. Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis. J Antimicrob Chemother 1999; 44: 501-13.
- Burke T, Villanueva C, Mariano H et al. Comparison of Moxifloxacin and Cefuroxime Axetil in the treatment of acute maxillary sinusitis. Clinical therapeutics, 1999; vol. 21; 10: 1664-77
- Vohr H, Wasinka-Kempka G, Ahr H. Studies on the Phototoxic Potential of a new 8-Methoxy-quinolone: BAY 12-8039. Proceedings of the 36th ICAAC, 1996; New Orleans, USA; p. 103.
- Man I, Murphy J, Fergeson J. Fluoroquinolone phototoxicity: a comparison of moxifloxacin and lomefloxacin in normal volunteers. J Antimicrob Chemother 1999; 43 (Suppl. B): 77-82.
- Siepmann M, Kirch W. Tachycardia associated with moxifloxacin. BMJ 2001; 322: 23.
- Ferguson J, Alajmi H, Kubin R, Dagget S et al. A double-blind, placebo- and lomefloxacin-controlled human volunteer phototest study to determine the photosensitising potential of oral moxifloxacin (BAY 12-8039). Proceedings of the 8th ICID9, 1998; Boston, USA; p. 197.
- Kubitza D, Delesen H. Influence of oral moxifloxacin on the QTs interval of healthy volunteers. Proceedings of the 40th ICAAC, 2000; Toronto, Canada; p. 475.
- Hollister A, Haverstock D, Choudhri S. Moxifloxacin has a favorable cardiovascular safety profile in patients taking concominant QTs prolonging drugs. Proceedings of the 40th ICAAC8; 2000 Sep 17-20; Toronto, Canada. p. 476.
- Beyer G, Hiemer-Bau M, Ziege S, Edlund C et al. Impact of moxifloxacin versus clarithromycin on normal oropharyngeal microflora. Eur J Clin Microbiol Infect Dis 2000; 19: 548-50.
- Edlund C, Beyer G, Hiemer-Bau M, Ziege S et al. Comparative effects of moxifloxacin and clarithromycin on normal intestinal microflora. Scan J Infect Dis 2000; 32: 81-5.
- Heystek M, Tellarini M, Schmitz H, Krasemann C. Efficacy and safety of moxifloxacin vs ciprofloxacin plus doxycycline plus metronidazole for the treatment of uncomplicated pelvic inflammatory disease (PID). J Antimicrob Chemother 1999; 44 (Suppl. A): 143.
- Ross JDC, Cronje HS, Paskowski T et al. Moxifloxacin versus ofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease: results of a multicentre, double-blind, randomized trial. Sex Transm Infect 2006; 82: 446-51.